ArticleFrontiers in medicine2026
Circulating selectins as potential biomarkers for sarcopenia: a case-control study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigates the association between circulating E-selectin, L-selectin, and P-selectin levels and sarcopenia in older adults. Methods: We conducted a case-control study of 325 older adults (261 controls, 64 sarcopenia cases). Sarcopenia was diagnosed using Asian Working Group for Sarcopenia 2019. Serum selectin concentrations were measured by ELISA. Diagnostic utility was assessed via ROC curve analysis, and associations were examined using logistic regression models. Results: Serum P-selectin was significantly elevated in sarcopenic participants compared to controls (19.76 ± 10.07 vs. 13.12 ± 7.39 ng/mL, Conclusion: Circulating P-selectin represents a novel, independent biomarker for sarcopenia, reflecting endothelial activation and inflammatory pathways underlying muscle wasting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.